
$PMN ProMIS Neurosciences Inc. is a biotechnology company headquartered in Canada. PMN310: A monoclonal antibody targeting Alzheimer's disease, currently in Phase 1b clinical trial (PRECISE-AD), is expected to release interim results in the first half of 2026 and top-line data by the end of the year. $PMN is a high-volatility penny stock suitable for investors with a high risk tolerance.



















